After the release of encouraging topline safety results from the Phase 1 SB101 clinical study of SON-1010, shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN)
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) has seen a significant boost in share price, with the stock rising to $6.11, or a 20.28% increase. The
Sonnet Bio Therapeutics Holdings Inc. (SONN) had a bullish day on April 12, 2022, with gains spreading over both the regular and after-hours sessions. The
Sonnet BioTherapeutics Holdings, Inc. (SONN) is engaged in the development of novel drugs for cancer therapeutics. Its Fully Human Albumin Binding technology utilizes a human single-chain
Sonnet BioTherapeutics Holdings, Inc. (SONN) experienced an increase of 5.75% in the aftermarket because the company announced the fiscal year 2022 first-quarter business updates. However,
Sonnet BioTherapeutics Holdings, Inc. (SONN) is focused on novel drugs for cancer therapeutics. The company’s Fully Human Albumin Binding technology uses a fully human single-chain
Sonnet BioTherapeutics Holdings, Inc. (SONN) today announced the completion of Licensing agreement with New Life Therapeutics(NLT) after which the SONN stock price saw an uptrend
China Automotive Systems Inc. (CAAS) stock soared 2.38% to $10.75 in the pre-market trading after reporting that it shipped approximately 120,000 units from its portfolio
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.